Skip to main content

Procainamide Pregnancy and Breastfeeding Warnings

Brand names: Procan SR, Procanbid, Pronestyl, Pronestyl-SR

Medically reviewed by Drugs.com. Last updated on Sep 4, 2023.

Procainamide Pregnancy Warnings

Procainamide (PA) has been used safely in the third trimester of pregnancy for the treatment of ventricular tachycardia. PA crosses the human placenta. There are no reports of congenital anomalies or adverse fetal effects associated with the use of procainamide during human pregnancy. Since PA is a weak base and fetal blood is slightly more acidic than maternal, "trapping" of PA in the fetus is suspected. In one patient who was taking PA 2,000 mg orally every 6 hours, maternal and umbilical mixed blood PA levels were 6.0 and 6.4 mcg per milliliter at delivery, respectively. Corresponding values for NAPA were 9.4 and 8.7 mcg per milliliter, respectively. Without a dose change or difference in renal function, the maternal serum PA and NAPA levels 37 days postpartum were 10.3 and 8.8 mcg per milliliter, suggesting altered pharmacokinetics of PA during pregnancy.

Procainamide has been assigned to pregnancy category C by the FDA. Animal studies have not been reported. There are no controlled data in human pregnancy. Procainamide should only be given during pregnancy when benefit outweighs risk.

See references

Procainamide Breastfeeding Warnings

Limited data from one woman who was taking procainamide (PA) 500 mg orally every 6 hours reveals that the concentrations of both PA and NAPA are lower in serum than in simultaneously collected milk specimens. The mean milk to maternal serum ratios for PA and NAPA were 4.3 and 3.8, respectively. Based on the usual therapeutic range for PA of 4 to 8 mg per liter, a regimen of 2 grams daily is estimated to result in maximal milk PA and NAPA levels of 34.4 and 30.4 mg per liter, respectively. Assuming 100% absorption and consumption of one liter per day (unlikely), the predicted plasma concentration in the nursing infant is less than 1 mg per liter.

Procainamide and N-acetylprocainamide (NAPA), an active metabolite, are excreted into and accumulate in human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

See also

References for pregnancy information

  1. Rotmensch HH, Elkayam U, Frishman W. Antiarrhythmic drug therapy during pregnancy. Ann Intern Med. 1983;98:487-97.
  2. Allen NM, Page RL. Procainamide administration during pregnancy. Clin Pharm. 1993;12:58-60.
  3. Product Information. Procan SR (procainamide). Parke-Davis. 2001;PROD.
  4. Page RL. Treatment of arrhythmias during pregnancy. Am Heart J. 1995;130:871-6.

References for breastfeeding information

  1. Rotmensch HH, Elkayam U, Frishman W. Antiarrhythmic drug therapy during pregnancy. Ann Intern Med. 1983;98:487-97.
  2. Product Information. Procan SR (procainamide). Parke-Davis. 2001;PROD.
  3. Product Information. Pronestyl (procainamide). Apothecon Inc. 2001;PROD.
  4. Pittard WB, Glazier H. Procainamide excretion in human milk. J Pediatr. 1983;102:631-3.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer